ArticleFrontiers in immunology2026
Analysis of influencing factors for syphilis serofast and development and evaluation of a predictive model.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With the rising incidence of syphilis in recent decades, the number of patients with syphilis serofast has also increased, posing challenges to clinical management of patients and increasing the social burden. Objective: In this study, we aimed to analyze influencing factors associated with syphilis serofast, develop and validate a predictive model for clinical prevention of syphilis serofast. Methods: A total of 373 syphilis patients were selected as the study subjects. Using a multivariate logistic regression model to analyze the relevant influencing factors of syphilis serofast, and the receiver operating curve (ROC) was used to evaluate the predictive performance of relevant influencing factors for syphilis serofast. Additionally, 187 syphilis patients were selected to verify the performance of the aforementioned model. Results: Among the 373 syphilis patients, serofast occurred in 134 patients (35.92%). Multivariate logistic analysis indicated that syphilis stage (SS), baseline TRUST titer (BTT), and TRUST titer changes at three months post-treatment (TTC-3M) were closely associated with the occurrence of syphilis serofast. Further ROC curve analysis revealed that the combined prediction of serofast by these three factors yielded an area under the ROC curve of 0.87 (95% CI: 0.84-0.91, P < 0.001). Subsequently, the predictive performance of the aforementioned model was evaluated, achieving an actual sensitivity of 0.88 and a specificity of 0.81 in 187 syphilis patients. Conclusions: SS, BTT, and TTC-3M are key factors influencing the occurrence of syphilis serofast. The predictive model constructed based on these three factors exhibits good efficacy and possesses clinical application value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.